Francesco Bertoni researcher
Bertoni, Francesco.
VIAF ID: 23983937 (Personal)
Permalink: http://viaf.org/viaf/23983937
Preferred Forms
-
- 100 1 _ ‡a Bertoni, Francesco
- 100 1 _ ‡a Bertoni, Francesco
- 100 1 _ ‡a Bertoni, Francesco
-
- 100 0 _ ‡a Francesco Bertoni ‡c researcher
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Al ... card. Luigi Amat ... | |
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. | |
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. | |
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas | |
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. | |
Incidence, risk factors and outcome of histological transformation in follicular lymphoma | |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma | |
Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog | |
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array | |
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma | |
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. | |
Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma | |
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance | |
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. | |
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? | |
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. | |
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. | |
Let's give BACH2 a breath of fresh air. | |
Life expectancy of young adults with follicular lymphoma | |
Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization | |
Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type | |
Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. | |
MALT lymphomas | |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes | |
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study | |
Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. | |
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. | |
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial | |
Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. | |
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. | |
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia | |
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. | |
Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas | |
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. | |
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness | |
MYC network mutations in high-risk chronic lymphocytic leukaemia | |
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. | |
Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. | |
Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms | |
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. | |
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. | |
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation | |
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax | |
Oncogenic BARD1 isoforms expressed in gynecological cancers | |
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations | |
Patterns of survival of follicular lymphomas at a single institution through three decades. | |
PCSF: An R-package for network-based interpretation of high-throughput data. | |
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. | |
Philosophia naturalis Io. Duns Scoti | |
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals | |
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas | |
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma | |
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. | |
Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials | |
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors | |
Prognostic impact of monocyte count at presentation in mantle cell lymphoma. | |
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. | |
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas | |
Risk factors of central nervous system relapse in mantle cell lymphoma | |
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type | |
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. | |
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases | |
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas | |
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma | |
Staining the target: CD37 expression in lymphomas. | |
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma | |
State-of-the-art therapeutics: marginal-zone lymphoma. | |
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome | |
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma | |
The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells. | |
Syk expression patterns differ among B-cell lymphomas | |
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. | |
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes | |
Toward new treatments for mantle-cell lymphoma? | |
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. | |
The transcription factor ETS1 in lymphomas: friend or foe? | |
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. | |
Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach | |
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. |